NOTICE 1 페이지

NEWS & EVENT

Total 11 - 1 page

No	Subject	Date	Hit
11	Ildong Pharmaceutical Invests KRW 13,000,000,000 in iLeadBMS to Strengthen the Ecosystem of Novel Drug R&D	2021.07.15	4,266
익명 4,266 2021.07.15
10	iLeadBMS Announces Results of TPD Molecular Glue Research of IL2106 (CDK12 Molecular Glue and Cyclin-K degrader) at ESMO TAT 2024	2024.02.27	3,059
익명 3,059 2024.02.27
9	iLeadBMS’ Cyclin-K Molecular Glue Receives ODD from FDA for Gastric Cancer	2024.10.07	2,692
익명 2,692 2024.10.07
8	Ildong Pharmaceutical Group’s ‘iLeadBMS’ Presents Non-Clinical Results of its Novel NASH Drug Candidate at the AASLD	2022.11.09	2,353
익명 2,353 2022.11.09
7	iLeadBMS Announces Positive Preclinical Results of IL1512 (CXCR7 Agonist) at the ATS 2024	2024.05.21	2,305
익명 2,305 2024.05.21
6	iLeadBMS Announces Positive Liver Fibrosis Results of IL1512 (CXCR7 Agonist) at the EASL 2024	2024.07.10	2,199
익명 2,199 2024.07.10
5	iLeadBMS Announces Orphan Drug Designation Granted by the FDA for IL21120033 (CXCR7 Agonist) for Idiopathic Pulmonary Fibrosis	2025.02.13	2,105
익명 2,105 2025.02.13
4	iLeadBMS Presents Preclinical Data on IL21120033, a First-in-Class ACKR3 Ago-PAM at EULAR 2025	2025.06.14	1,889
익명 1,889 2025.06.14
3	iLeadBMS Presents Preclinical Data on IL21120033 for Heart Failure at ACC 2025	2025.03.31	1,843
익명 1,843 2025.03.31
2	iLeadBMS Presents Preclinical Data on Novel Drug Candidate for Heart Failure at AFDD	2024.11.21	1,839
익명 1,839 2024.11.21
1	신주발행공고	2025.12.29	376
익명 376 2025.12.29

INVESTORS & MEDIA